Cable Car Capital LP Makes New Investment in ImageneBio, Inc. $IMA

Cable Car Capital LP purchased a new position in shares of ImageneBio, Inc. (NASDAQ:IMA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 781,599 shares of the company’s stock, valued at approximately $4,611,000. Cable Car Capital LP owned about 7.34% of ImageneBio as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of IMA. Geode Capital Management LLC increased its position in ImageneBio by 13.5% during the fourth quarter. Geode Capital Management LLC now owns 54,146 shares of the company’s stock worth $374,000 after acquiring an additional 6,458 shares during the period. Barclays PLC boosted its holdings in ImageneBio by 170.8% in the 4th quarter. Barclays PLC now owns 10,797 shares of the company’s stock valued at $74,000 after purchasing an additional 6,810 shares during the period. Goldman Sachs Group Inc. acquired a new stake in ImageneBio in the 4th quarter worth $76,000. Millennium Management LLC acquired a new stake in ImageneBio in the 4th quarter worth $79,000. Finally, Bridgeway Capital Management LLC bought a new position in shares of ImageneBio during the 3rd quarter worth about $104,000. 75.00% of the stock is owned by institutional investors.

Trending Headlines about ImageneBio

Here are the key news stories impacting ImageneBio this week:

• Positive Sentiment: HC Wainwright initiated research coverage with a Buy rating and a $28 price target, substantially above the stock’s recent trading level. The firm expects ImageneBio to continue reporting losses but is maintaining a bullish view on the company’s longer-term prospects. ImageneBio Research Coverage Started at HC Wainwright
• Positive Sentiment: Reported short interest fell 87.2% to 49,297 shares as of August 14, representing only 0.4% of shares outstanding. The reduction lowers potential selling pressure and suggests fewer investors are betting against IMA, although the stock’s low trading volume limits the significance of the change.
• Neutral Sentiment: A separate report listed short interest at zero shares as of August 25, unchanged from zero previously. Because the report describes the change as “NaN” and conflicts with the August 14 figures, it appears to be a data-quality issue rather than a meaningful market development.
• Negative Sentiment: HC Wainwright’s detailed forecasts point to continued and potentially widening losses: EPS estimates are negative at $(3.57) for FY2026, $(5.48) for FY2027, and remain negative through FY2030. Persistent cash-burn and the absence of near-term profitability remain important risks, even with the firm’s Buy rating.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on IMA. Wall Street Zen lowered shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. HC Wainwright started coverage on ImageneBio in a research report on Friday. They set a “buy” rating and a $28.00 target price on the stock. Wedbush restated an “underperform” rating on shares of ImageneBio in a research note on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $29.00.

ImageneBio Price Performance

IMA opened at $5.55 on Wednesday. The company has a market capitalization of $62.99 million, a P/E ratio of -1.21 and a beta of 0.76. The firm’s fifty day moving average price is $5.79 and its two-hundred day moving average price is $5.83. ImageneBio, Inc. has a fifty-two week low of $3.94 and a fifty-two week high of $14.00.

ImageneBio (NASDAQ:IMA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.27. On average, equities research analysts expect that ImageneBio, Inc. will post -3.23 EPS for the current fiscal year.

ImageneBio Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.